Eli Lilly has seen weakness in its stock price year to date. I think it's a short-term problem.It's not often that something as influential as an effective weight loss drug comes on the market. Eli Lilly (LLY -0.20%) has that product. They also have a leading treatment for diabetes and a burgeoning treatment for Alzheimer's. These multiple treatment avenues have the company set to rake in quite a bit of money as long as they don't screw it up.My general take here is that the remarkable revenue growth we saw ...